Key result
First-line treatment of essential hypertension with RAS blockers or diuretics was associated with lower cardiovascular event rates (5.4% and 5.2%) compared to beta blockers (9.5%).
Why the study?
The relative efficacy of antihypertensive treatment has been assessed primarily by randomized clinical trials, prompting the use of electronic medical records to compare RCT results to actual clinical practice.
Does the choice of first-line antihypertensive class (diuretics, beta blockers, RAS inhibitors, or calcium channel blockers) affect the rate of cardiovascular events and blood pressure control in patients with essential hypertension?
Cohort (n=79,288)
Yes
Does the choice of first-line antihypertensive class (diuretics, beta blockers, RAS inhibitors, or calcium channel blockers) affect the rate of cardiovascular events and blood pressure control in patients with essential hypertension?
Absolute Event Rate: 5.4% vs 9.5%
Real-world data confirms that RAS inhibitors and diuretics are highly effective first-line agents for essential hypertension, whereas beta blockers are associated with poorer blood pressure control and higher cardiovascular event rates.
No takes yet. Share an insight, caveat, or question.
Supports RAS blockers or diuretics over beta blockers in essential hypertension; hypothesis-generating and requires randomized confirmation before practice change.
Stapff et al. (2019) conducted a cohort in essential hypertension (n=79,288). RAS blockers or diuretics vs. Beta blockers was evaluated on Cardiovascular (CV) events. First-line treatment of essential hypertension with RAS blockers or diuretics was associated with lower cardiovascular event rates (5.4% and 5.2%) compared to beta blockers (9.5%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: